A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Dihydrocapsiate does not increase energy expenditure nor fat oxidation during aerobic exercise in men with overweight/obesity: a randomized, triple-blinded, placebo-controlled, crossover trial
Tekijät: Osuna-Prieto Francisco J, Acosta Francisco M, Le Floc'h Unai A Perez De Arrilucea, Riquelme-Gallego Bianca, Merchan-Ramirez Elisa, Xu Huiwen, De La Cruz-Marquez Juan Carlos, Amaro-Gahete Francisco J, Llamas-Elvira Jose A, Trivino-Ibanez Eva M, Segura-Carretero Antonio, Ruiz Jonatan R
Kustantaja: Taylor & Francis Inc
Julkaisuvuosi: 2022
Journal: Journal of the International Society of Sports Nutrition
Tietokannassa oleva lehden nimi: JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION
Lehden akronyymi: J INT SOC SPORT NUTR
Vuosikerta: 19
Numero: 1
Aloitussivu: 417
Lopetussivu: 436
Sivujen määrä: 20
eISSN: 1550-2783
DOI: https://doi.org/10.1080/15502783.2022.2099757
Verkko-osoite: https://doi.org/10.1080/15502783.2022.2099757
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/176021306
Background Prior evidence suggests that capsinoids ingestion may increase resting energy expenditure (EE) and fat oxidation (FATox), yet whether they can modulate those parameters during exercise conditions remains poorly understood. We hypothesized that dihydrocapsiate (DHC) ingestion would increase EE and specifically FATox during an acute bout of aerobic exercise at FATmax intensity (the intensity that elicits maximal fat oxidation during exercise [MFO]) in men with overweight/obesity. Since FATmax and MFO during aerobic exercise appear to be indicators of metabolic flexibility, whether DHC has an impact on FATox in this type of population is of clinical interest. Methods A total of 24 sedentary men (age = 40.2 +/- 9.2 years-old; body mass index = 31.6 +/- 4.5 kg/m(2) [n = 11 overweight, n = 13 obese]) participated in this randomized, triple-blinded, placebo-controlled, crossover trial (registered under ClinicalTrials.gov Identifier no. NCT05156697). On the first day, participants underwent a submaximal exercise test on a cycle ergometer to determine their MFO and FATmax intensity during exercise. After 72 hours had elapsed, the participants returned on 2 further days (>= 72 hours apart) and performed a 60 min steady-state exercise bout (i.e. cycling at their FATmax, constant intensity) after ingesting either 12 mg of DHC or placebo; these conditions were randomized. Respiratory gas exchange was monitored by indirect calorimetry. Serum marker concentrations (i.e. glucose, triglycerides, non-esterified fatty acids (NEFAs), skin temperature, thermal perception, heart rate, and perceived fatigue) were assessed. Results There were no significant differences (P > 0.05) between DHC and placebo conditions in the EE and FATox during exercise. Similarly, no significant changes were observed in glucose, triglycerides, or NEFAs serum levels, neither in the skin temperature nor thermal perception across conditions. Heart rate and perceived fatigue did not differ between conditions. Conclusions DHC supplementation does not affect energy metabolism during exercise in men with overweight/obesity.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
